Pfizer Inc. (NYSE:PFE) has received a consensus rating of “Buy” from the twenty-six brokerages that are covering the stock. Ten analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $38.80.
A number of brokerages have recently issued reports on PFE. Bank of America Corp. reaffirmed a “buy” rating and set a $40.00 target price on shares of Pfizer in a research report on Tuesday. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Pfizer in a research report on Monday, September 26th. Jefferies Group dropped their target price on Pfizer from $40.00 to $39.00 and set a “buy” rating on the stock in a research report on Tuesday, September 13th. Argus reaffirmed a “buy” rating and set a $39.00 target price on shares of Pfizer in a research report on Sunday, August 28th. Finally, Piper Jaffray Cos. set a $54.00 target price on Pfizer and gave the stock a “buy” rating in a research report on Tuesday, August 23rd.
Several institutional investors have recently modified their holdings of PFE. Nelson Roberts Investment Advisors LLC boosted its stake in shares of Pfizer by 6.7% in the second quarter. Nelson Roberts Investment Advisors LLC now owns 2,999 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 189 shares during the last quarter. Stelac Advisory Services LLC purchased a new stake in shares of Pfizer during the second quarter valued at approximately $110,000. Tuttle Tactical Management LLC purchased a new stake in shares of Pfizer during the second quarter valued at approximately $117,000. Catamount Wealth Management boosted its stake in shares of Pfizer by 14.2% in the first quarter. Catamount Wealth Management now owns 4,395 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 545 shares during the last quarter. Finally, Delphi Private Advisors LLC boosted its stake in shares of Pfizer by 1.2% in the second quarter. Delphi Private Advisors LLC now owns 4,007 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 47 shares during the last quarter. Institutional investors and hedge funds own 69.65% of the company’s stock.
Shares of Pfizer (NYSE:PFE) opened at 33.87 on Wednesday. The firm has a 50-day moving average price of $34.48 and a 200 day moving average price of $34.04. The firm has a market capitalization of $205.44 billion, a price-to-earnings ratio of 30.03 and a beta of 0.87. Pfizer has a one year low of $28.25 and a one year high of $37.39.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.62 by $0.02. Pfizer had a return on equity of 23.37% and a net margin of 14.88%. The company had revenue of $13.10 billion for the quarter, compared to analyst estimates of $13.01 billion. During the same period last year, the company posted $0.56 earnings per share. The firm’s revenue was up 10.9% compared to the same quarter last year. Equities analysts forecast that Pfizer will post $2.46 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 1st. Stockholders of record on Friday, November 11th will be given a dividend of $0.30 per share. The ex-dividend date of this dividend is Tuesday, November 8th. This represents a $1.20 annualized dividend and a dividend yield of 3.54%. Pfizer’s dividend payout ratio is presently 95.24%.
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.